Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Fosun Pharma Considering $500 Million IPO of Gland Pharma

publication date: Jul 20, 2018

Shanghai Fosun Pharma is considering an IPO of one of its recent acquisitions, the Indian drugmaker Gland Pharma, according to a Bloomberg report. If it decides to move ahead on the transaction, Fosun would seek to raise $500 million in an initial offering on an Indian exchange. In 2017, Fosun paid $1.1 billion for 74% ownership of Gland, a company known for its generic injectable products. More details....

Stock Symbols: (SHA: 600196; HK: 02196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.